Meta-Analysishigh evidence
Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·July 11, 2026·PMID 42432163
Why it mattersPreclinical promise of GLP-1 agonists for neuroprotection in Parkinson's disease has generated clinical interest, but this synthesis of phase 3 data clarifies that current agents lack symptomatic or disease-modifying efficacy in the broader PD population while posing notable risks of weight loss.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled